Pancreatic Cancer Trial, Recruiting NCT05428358 Sponsor: University of Aarhus Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT05428358
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have pancreatic cancer where the tumour has been assessed by a specialist medical team as removable by surgery, or close to being removable by surgery
  • People whose CT scan shows no cancer spread to the liver
  • People who are at least 18 years old and are able to agree to participate in the study
  • People whose CT scan suggests they likely have a specific type of pancreatic cancer called pancreatic ductal adenocarcinoma

Who may not be able to join:

  • People whose cancer has spread to other parts of the body
  • People who have already received chemotherapy or other treatments aimed at shrinking the tumour before surgery
  • People whose other health conditions mean that major surgery is not considered safe or possible
  • People who are not willing or able to give their consent to participate
  • People who are unable to have an MRI scan, which may include those with reduced kidney function (confirm with trial site), claustrophobia, or a cardiac pacemaker
  • People whose tissue sample taken after surgery shows a cancer type other than adenocarcinoma of the pancreatic or bile duct region
  • People who have already had a particular type of MRI scan using a liver-specific contrast dye as part of their standard medical assessment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Frank Mortensen, MD, DMSc, Aarhus University Hospital

Phone: +4522900604

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
30 August 2022
Est. completion
1 December 2027

Where this trial is recruiting

🇩🇰 Denmark

Primary endpoints

Change in treatment strategy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov